https://www.selleckchem.com/products/ms8709.html
After propensity score matching, the average daily and cumulative dose, treatment duration, and dosing interval for L-AMB were not significantly different between patients receiving and not receiving RRT. L-AMB was used as the first-line antifungal agent for patients undergoing CRRT in most cases (12/19; 63%). Although the number of subjects was limited, the incidence of adverse events did not markedly differ among the groups. L-AMB may be used for patients undergoing maintenance HD or CRRT without any dosing, duration, or interval adjus
Like
Comment
Share
